(TheNewswire)
Winnipeg – TheNewswire - March 1 , 2024 — Cytophage Technologies Ltd. (“Cytophage” or the“Company”) (TSXV:CYTO) is pleased to announce that it iscollaborating with infectious diseases clinician-scientist, Dr. MarisaAzad (Principal Investigator), at The Ottawa Hospital to deliver –for the first time in Canada – bacteriophage (phage) therapy to apatient suffering from a severe hardware-associated bone and jointinfection, with approval from Health Canada and The Ottawa HospitalResearch Institute.
The applicability of phage therapy to prosthetic jointinfections has been a core area of research for Cytophage. In late 2023, Cytophage was contacted by Dr. Azad who had a patientsuffering from an antibiotic resistant infection associated with aprosthetic joint replacement. A treatment plan was developed andapproved by The Ottawa Hospital ResearchInstitute and Health Canada to be delivered as asingle subject clinical trial (N of 1). This allows for anindividual patient to be the sole unit of observation in a studyinvestigating the efficacy of a course of treatment when all othertreatments have failed. The patient received the first dose this weekand will continue to receive treatments for two weeks. The treatment plan includes phages that have beenexclusively provided by Cytophage and have been rigorously tested fortheir ability to destroy MRSE(methicillin-resistant Staphylococcus epidermidis ) bacteria.
“This is a n importantbreakthrough for people who suffer fromdrug-resistant prosthetic joint infections in that a new treatmentregime is being introduced that will target these difficult to treatinfections” says Dr. Steven Theriault, CEO of Cytophage. “We hopeto make a significant difference in the quality of life of patientswho are living with this type of infection.”
According to the Canadian Institute for Health Information (CIHI), over 130,000 hip and knee replacementsurgeries are performed every year in Canada. Although effective inrestoring function and improving quality of life, about 3 % of surgeries may require additionalintervention in the form of treatment of antibiotic resistantprosthetic joint infections, a devastating complication that, if leftunresolved, can lead to amputation and even death.
Cytophage acknowledges the tremendous work of Dr. Azadand the team at The Ottawa Hospital ResearchInstitute. The Company is optimistic that this will be the first of aseries of N of 1 studies for prosthetic joint infections, as well asalso other difficult to treat infections.
As Dr. Theriault notes, “WhileCytophage’s current focus remains on animal health and improvingfood security, the use of our phages in the treatment of humaninfections reinforces the potential of bacteriophages as an efficientalternative and/or complement to antibiotics.”
Cytophage is also announcing thatit has entered into a marketing and market awareness agreement (the"Agreement") with the CanaCom Group. Pursuant to the terms of the Agreement, theservices are to be provided over a 12-month period, commencing onFebruary 12, 2024, for a fee of $90,000, plus applicable taxes.CanaCom is a full-service marketing agency based in Toronto, Ontario.CanaCom provides digital marketing awareness via advertising throughits fully owned platform theDeepDive.ca, which includes both video andwritten content coverage of Canadian small-cap stories. CanaCom holdsapproximately 60,316 of the Company's outstanding common shares and isotherwise an arm's length service provider to the Company. CanaCom hasits principal place of business at 1836 Scarth Street, Regina, SK S4P3G3. They can be contacted at jay@thedeepdive.ca or by telephone at(306) 993-4791.
For media inquiries:
Heather Medwick
Chief Operating Officer
heather@cytophage.com
431 388 8873
About Cytophage
Cytophage is a pioneering biotechnology company dedicated tobacteriophage research, product development and commercialization.Committed to addressing the global challenge of antibiotic resistance,Cytophage advances innovative products that harness the power ofbacteriophages to combat bacterial infections affecting human health,animal health, and food security.
Cautionary Statement on Forward-Looking Information
This news release contains “forward-looking information” and“forward-looking statements” (collectively, “forward-lookingstatements”) within the meaning of the applicable Canadiansecurities legislation. All statements, other than statements ofhistorical fact, are forward-looking statements and are based onexpectations, estimates and projections as at the date of this newsrelease. Any statement that involves discussions with respect topredictions, expectations, beliefs, plans, projections, objectives,assumptions, future events or performance (often but not always usingphrases such as “expects”, or “does not expect”, “isexpected”, “anticipates” or “does not anticipate”,“plans”, “budget”, “scheduled”, “forecasts”,“estimates”, “believes” or “intends” or variations of suchwords and phrases or stating that certain actions, events or results“may” or “could”, “would”, “might” or “will” betaken to occur or be achieved) are not statements of historical factand may be forward-looking statements. Forward-looking statementsinvolve known and unknown risks, uncertainties and other factors whichmay cause the actual results, performance or achievements of Cytophageto be materially different from any future results, performance orachievements expressed or implied by the forward-looking statements.Factors that could cause actual results to differ materially fromthose anticipated in these forward-looking statements are describedunder the caption “Risk Factors” in Cytophage’s Filing Statementdated January 30, 2024, which is available for view on SEDAR+ atwww.sedarplus.ca. These risks include but are not limited to, therisks associated with the bacteriophage industry, such as operationalrisks in development or capital expenditures, the uncertainty ofextensive regulatory approval requirements, government regulations,protection of intellectual property, product liability and rapidtechnological advancements. Forward-looking statements containedherein are made as of the date of this press release, and Cytophagedisclaims, other than as required by law, any obligation to update anyforward-looking statements whether as a result of new information,results, future events, circumstances, or if management’s estimatesor opinions should change, or otherwise. There can be no assurancethat forward-looking statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, the reader is cautionednot to place undue reliance on forward-looking statements. Neither theTSXV nor its Regulation Services Provider (as that term is defined inthe policies of the TSXV) accepts responsibility for the adequacy oraccuracy of this news release.
Copyright (c) 2024 TheNewswire - All rights reserved.